Adjuvant Drug Treatment for Resectable Breast Cancer.

Area of Science:

• Oncology
• Medical Malignancies

Background:

• Breast cancer is a prevalent and deadly malignancy in Western women.
• A significant challenge is the high rate of relapse and death post-initial curative surgery.
• Current standard treatments include surgery, radiation, and systemic drug therapies like tamoxifen and chemotherapy.

Purpose of the Study:

• To address the paradox of initial curability versus later relapse in breast cancer.
• To highlight the impact and limitations of current systemic drug therapies.
• To emphasize the importance of ongoing research and clinical trials for advancing breast cancer treatment.

Main Methods:

• Review of current standard treatment options for breast cancer.
• Discussion of systemic drug therapies including tamoxifen and combination chemotherapy.
• Exploration of ongoing research areas such as high-dose and dose-dense chemotherapy, and novel agents.

Main Results:

• Current treatments, while impactful, do not prevent relapse in a significant number of patients.
• Systemic therapies like tamoxifen and chemotherapy are standard for specific patient subgroups.
• Despite optimal treatment, a substantial proportion of patients still experience disease recurrence.

Conclusions:

• Further advancements in breast cancer treatment are critically needed.
• Ongoing research into novel therapeutic approaches and clinical trials is essential.
• Improving systemic drug therapy offers the best prospect for reducing breast cancer mortality and enhancing patient outcomes.